Friday, August 14, 2026
Facts you can rely on·101 entities·4,806 sourced facts
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 16, 2026

Cardiovascular Devices Market Projected to Reach US$ 157.32 Billion by 2035, Supported by Expanding Clinical Research Activity Says Astute Analytica

View original at globenewswire.com
Cardiovascular Devices Market Projected to Reach US$ 157.32 Billion by 2035, Supported by Expanding Clinical Research Activity Says Astute Analytica Chicago, Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • As of December 2025, over 2,000 cardiovascular drugs and device-delivery therapies were in active development

    80% confidence
  • Varipulse achieved an 80% recurrence-free rate

    80% confidence
  • FDA cleared a record 39 new clinical AI algorithms in May 2025, bringing the total to 116 cleared cardiology algorithms

    80% confidence
  • North America secured the largest geographical portion, contributing 45.68% of the revenue share in 2025

    80% confidence
  • Vascular device investment reaching USD 759 million and cardiovascular venture investment stabilizing at USD 542 million in 2024

    80% confidence
  • FDA listed 1,176 devices in its Breakthrough Device Program as of August 2024, with 243 designations specifically allocated to cardiovascular innovations

    80% confidence
  • US market for smart wearable ECG monitors was valued at USD 586.91 million in 2024

    80% confidence
  • Total US cardiovascular deaths hit 931,578 with age-adjusted death rate rose to 233.3 per 100,000

    80% confidence
  • A 2025 analysis identified 51 major cardiovascular clinical trials published between 2019 and 2024, enrolling a total of 292,985 patients

    80% confidence
  • Medtronic's PulseSelect demonstrated an average skin-to-skin procedure time of just 36 minutes in 2024 with 98% of pulmonary veins remained isolated

    80% confidence
  • New clinical trial initiations surged by 68% in the decade ending 2024

    80% confidence
  • Boston Scientific's Farapulse procedures finished in under 90 minutes in 90% of cases, while thermal ablation only achieved this speed in 60% of cases

    80% confidence
  • Projected global healthcare cost savings from wearable adoption estimated at USD 200 billion over the next 25 years

    80% confidence
  • MANIFEST-17K study reported a 0% rate of esophageal damage and pericardial tamponade rate of just 0.36%

    80% confidence
  • Global shipments of wearable health devices reached 440 million units in 2024, with 160 million units specifically designated as medical sensors for clinical monitoring

    80% confidence
  • China accounted for 22.26% of the global cardiovascular disease burden

    80% confidence
  • Total surgical procedure volumes reached 18.9 million in 2024, with the United States and China accounting for 3.6 million and 3.5 million interventions, respectively

    80% confidence
  • UK cardiac waiting list swelling to 421,433 patients by May 2024 and Canadian wait times reaching 194 days

    80% confidence
  • Stroke caused 162,890 deaths in the US

    80% confidence
  • FDA cleared 16 distinct breakthrough cardiovascular devices in the 12 months leading up to August 2024

    80% confidence
  • 92% of US smartwatch users utilize their device primarily for health tracking, with 37% specifically monitoring heart metrics

    80% confidence
  • Medical tourism options for TAVR in India were priced at approximately USD 14,500 in 2024

    80% confidence
  • 127.9 million US adults had some form of cardiovascular disease in 2024

    80% confidence
  • Weekly procedure rates averaging 16,200 cases throughout 2024 for pulsed field ablation

    80% confidence
  • 45% of global cath lab equipment exports originating from US manufacturers in 2024

    80% confidence
  • 46% of US counties operate without a single practicing cardiologist, while 86% of rural counties lack access entirely

    80% confidence
  • Average cost for a TAVR procedure in 2024 ranged from USD 52,176 in Chicago to USD 81,889 in California

    80% confidence
  • Nearly 12.1 million people in the US are projected to be diagnosed with Atrial Fibrillation by 2030

    80% confidence
  • The therapeutics & surgical devices category held a commanding position, accounting for a 77.5% revenue share in 2025

    80% confidence
  • The US supported 4,300 operational cardiac catheterization labs in 2024, while the number of hybrid cath labs globally reached 2,400

    80% confidence

Data points we hold from this source

U.S. Food and Drug Administration · cardiology ai algorithms total116 algorithms
U.S. Food and Drug Administration · ai algorithms cleared may 202539 algorithms
U.S. Food and Drug Administration · cleared breakthrough cvd devices 12mo16 devices
U.S. Food and Drug Administration · breakthrough cardiovascular devices243 devices
U.S. Food and Drug Administration · breakthrough devices total1176 devices
Cardiovascular Devices Market Projected to Reach US$ 157.32 Billion by 2035, Supported by Expanding Clinical Research Activity Says Astute Analytica — Source | Via News | Via News